Drug intelligence / Profile preview

LY3374849

Development stage: Phase 1
Lead developer: Eli Lilly
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous, Intravenous

Overview

LY3374849 is a long-acting monoclonal antibody developed by Eli Lilly that functions as an agonist of the insulin receptor (INSR). It is categorized as a Long-Acting Insulin Receptor Agonist (LAIRA) and was designed to provide sustained glycemic control, potentially offering a longer duration of action compared to traditional basal insulins like insulin degludec. The drug has been evaluated in Phase 1 clinical trials to assess its safety, pharmacokinetics, and glucodynamic effects in healthy subjects, where it was administered via both subcutaneous and intravenous routes.

Targets

INSR (Insulin receptor)

Beyond the preview

Go deeper on LY3374849.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LY3374849.

Explore the full profile